Zhao W, Xu J, Li S, et al. - In this prospective registry study, researchers tested the safety and effectiveness of low-dose tirofiban in cardioembolic stroke patients treated with endovascular thrombectomy (EVT). From January 2013 to December 2020, patients with cardioembolic stroke undergoing EVT were treated with EVT alone or EVT plus low-dose tirofiban. The primary outcome was symptomatic intracerebral hemorrhage (sICH) prior to discharge, whereas the secondary outcomes included reocclusion, in-hospital mortality, and 3-month functional outcomes. Overall, 288 patients were selected and 117 received low-dose tirofiban; 137 patients (47.6%) experienced ICH, 42 patients (14.6%) were sICH, and 23 patients (8%) were fatal ICH. Tirofiban does not appear to increase the risk of sICH in patients with cardioembolic stroke undergoing EVT, but it does appear to reduce the risk of in-hospital death. More research is needed to confirm these findings and determine the best tirofiban treatment protocols.